Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. (HALO) Stock Overview

Explore Halozyme Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

HALO●NASDAQ
HealthcareBiotechnology
$83.40
$1.13(1.38%)
U.S. Market is Open · 14:19

Halozyme Therapeutics, Inc. (HALO)

Meyka AI Score

Z

Key Financials

Market Cap9.9B
P/E Ratio28.43
EPS (TTM)$4.62
ROE1.26%
Fundamental Analysis

AI Price Forecasts

1 Month$88.76
3 Months$79.17
1 Year Target$80.94

HALO Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Halozyme Therapeutics, Inc. (NASDAQ: HALO) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of A, Halozyme Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of HALO on the NASDAQ shows an RSI of 65.67, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $80.94 for the NASDAQ listing.

Key metrics behind Halozyme Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of 28.43 and a market capitalization of 9.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of HALO on the NASDAQ.

Price Performance (NASDAQ: HALO)

1-Day Change
1.17%
5-Day Change
1.82%
1-Month Change
3.03%
3-Month Change
28.90%
6-Month Change
6.80%
Year-to-Date (YTD) Change
23.67%
1-Year Change
38.74%
3-Year Change
96.25%
5-Year Change
107.35%
All-Time (Max) Change
1858.35%

Contact Information

https://www.halozyme.com
858 794 8889
12390 El Camino Real, San Diego, CA, 92121

Company Facts

4,230 Employees
IPO DateMar 16, 2004
CountryUS
Actively Trading

Frequently Asked Questions